TY - JOUR T1 - Coronary revascularisation in patients with diabetes: a chance to be better JF - Evidence Based Medicine JO - Evid Based Med SP - e59 LP - e59 DO - 10.1136/eb-2013-101259 VL - 18 IS - 6 AU - Stephan Windecker AU - Giulio G Stefanini Y1 - 2013/12/01 UR - http://ebm.bmj.com/content/18/6/e59.abstract N2 - Commentary on: Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularisation in patients with diabetes. N Engl J Med 2012;367:2375–84.OpenUrlCrossRefPubMedWeb of Science In 2009, a pooled analysis of individual patient data from randomised clinical trials comparing percutaneous coronary interventions (PCI) with coronary artery bypass grafting (CABG) showed a survival benefit in favour of CABG.1 Techniques of both PCI and CABG evolved during the last decade with the use of drug-eluting stents (DES) and novel antiplatelet agents. In the FREEDOM trial, patients with diabetes and multivessel coronary artery disease (CAD) were randomised with concealed allocation to PCI with DES (94% sirolimus-eluting and paclitaxel-eluting stents) or CABG. Key exclusion criteria were left main stenosis, severe heart failure, acute myocardial infarction (MI), CK>2× normal, prior cardiac surgery or PCI, previous stroke, contraindication to CABG/DES and extracardiac illness with expected survival … ER -